drugset / Trial / NCT00149734
Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia
Phase 3
Completed
8 enrolled
University of Colorado, Denver
National Institute of Mental Health (NIMH) · collab
RandomizedCrossoverQuadruple-blindTreatment
Summary
This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics.
Timeline
- Start
- 2005-01
- Primary completion
- 2010-05
- Completion
- 2010-05
Publications
- Background Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, Waldo MC. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry. 2005 Feb;162(2):386-8. doi: 10.1176/appi.ajp.162.2.386.
- Background Adler LE, Olincy A, Cawthra EM, McRae KA, Harris JG, Nagamoto HT, Waldo MC, Hall MH, Bowles A, Woodward L, Ross RG, Freedman R. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients. Am J Psychiatry. 2004 Oct;161(10):1822-8. doi: 10.1176/ajp.161.10.1822.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ondansetron | Other / unclassified | 16 mg | — |
| Background | Aripiprazole | Other / unclassified | — | — |
| Background | Olanzapine | Small molecule | — | — |
| Background | Quetiapine | Small molecule | — | — |